No results on the company website, despite an RNS telling us they are there |
Slough, UK, and Richmond, VA, October 15, 2024 - Indivior PLC (NASDAQ/LSE: INDV) today announced that it will release its year-to-date and Q3 2024 results on October 24th at 7:00 a.m. London time (2:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com.Mark Crossley, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 1:00 p.m. London time (8:00 a.m. U.S. Eastern) on October 24th. |
Excellent article Waldron.
"An analysis of more than 500,000 people with a history of opioid-use disorder showed that more than 8,000 participants who were separately prescribed so-called GLP-1 drugs, such as Ozempic, had a 40 per cent lower rate of opioid overdose than those who did not.2 |
I still think a lot of the weakness in this and many other UK small caps is due to budget related issues (Capital gains tax, pension rule changes etc.) |
...and they are looking to cut costs and possibly cut prices to match the competition |
They no longer have the monopoly, the competition has eroded market share and will continually seek to further erode any market share and the company is swamped in litigation. The buyback I think will end in February, having commenced in August. |
just shows how pointless the move to the US stock market was |
still double the current price |
too cheap by any measure.. |
Deutsche Bank cuts Indivior price target to 1,250 (1,500) pence - 'buy' |
this is trading on an EV/Sales multiple of 0.8. Industry standard is at least 2 times. Very undervalued |
Listen to the webcast q&a. |
US close around 610p so hopefully some improvement tomorrow |
 Benjamin Chiou
Sharecast News
10 Oct, 2024 17:01
Europe close: Stocks inch lower after choppy session
Thursday saw choppy trading across European stock markets with the region's main benchmark finishing lower but moving within a narrow range, as investors focused on mixed economic data from the US and developments in the Middle East.
The Stoxx 600 index closed down 0.18% (0.94 points) at 519.11, with less than four points separating the intraday high (521.08) and low (517.81).
Wall Street stocks got off to a weak start after inflation and jobless claims data blurred the outlook for the next Federal Reserve policy decision.
Following last week's bumper payroll report, markets had begun to lower their expectations for another big rate cut from the Fed. But data out on Thursday showed that jobless claims had jumped to their highest since June 2023, reviving hopes that more policy action could be on the cards to ease the strain on the economy.
Nevertheless, figures showed that the annual rate of US consumer price inflation slowed to a three-and-a-half-year low of 2.4% in September, but still came in above the 2.3% expected, raising concerns that the fight against inflation might not be over just yet.
Meanwhile, oil prices were once again on the rise as tensions in the Middle East continued to escalate. Brent was up 2.1% at $78.19 a barrel by the close in Europe, after having pulled back sharply over recent days since topping the $80 mark on Monday.
“It looks increasingly likely that Israel will go for a large-scale attack on Iran, as reports emerge of Gulf states lobbying the US to rein in its ally," said Chris Beauchamp, chief market analyst at IG. "Oil prices have surged on hints that Israel is seeking to take advantage of the Iranian attack to deliver a major strike on its opponent. The consequences of that could include a closing of the Straits of Hormuz, leading to major disruption to oil supplies.”
Back in Europe, data showed that retail sales in Germany rose over the past two months. According to delayed data from the Federal Statistical Office, sales volumes increased by 1.6% during August, following a 1.5% gain in July and a 1.1% decline in June. Destatis released figures for the past three months in one go on Thursday after suspending a number of key economic indicators in May due to a failed IT systems update at the Wiesbaden-based authority.
Market movers
GSK was among the best performers on the Stoxx 600, rising 3% after the London-listed pharma giant agreed to settle about 93% of US cases in its Zantac lawsuits for up to $2.2bn. The settlement figure was close to the "best case scenario", according to Jefferies, which said the announcement should remove a significant weight on the share price.
Deutsche Telekom rose 2% on plans to lift its dividend and buy back shares on the back of better revenue expectations in the next three years.
Leading the fallers was UK pharma firm Indivior after delivering its second profit warning this year. Shares were down 19% after Indivior said it was seeing faster initial adoption among treatment providers of a competing long-acting injectable to its Sublocade treatment, as it cut its full-year sales and earnings targets |
4 year low. surely that is not justified? |
I think they also have some sort of 'pre-market' in the US. I don't think it'll be that volatile. |
US open maybe interesting. |
less than 0.6% of shares traded to bring it down 20% from an already low level |
Invest in stocks they say, make money they will.Not in 2024 ffs |
agreed, now in ridiculously cheap territory. added in meaningful way |
down 65% from year high. seems fully priced in |
They are no longer the only kid on the block and the Trump doesn't seem to like State funded medical help. |
All depends on your buy in price and time horizon. |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
